Sagimet Biosciences (SGMT) Total Liabilities (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Total Liabilities of $107.8 million for Q1 2026, up 1400.77% year-over-year from $7.2 million in Q1 2025, and down 7.49% quarter-over-quarter from $116.5 million in Q4 2025.
Sagimet Biosciences (SGMT) Total Liabilities (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Total Liabilities history runs 5 years deep, the most recent figure standing at $107.8 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 1400.77% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $107.8 million (up 1400.77% YoY), while the FY2025 annual figure was $116.5 million, up 2515.22% from the prior year.
- Total Liabilities for Q1 2026 stood at $107.8 million, down from $116.5 million in the prior quarter.
- The five-year high for Total Liabilities was $137.4 million in Q2 2025, with the low at $4.1 million in Q3 2024.
- The 5-year median for Total Liabilities is $5.7 million (2023), against an average of $41.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities declined 21.22% in 2024, then soared 3037.85% in 2025.
- Sagimet Biosciences' Total Liabilities stood at $5.4 million in 2022, then rose by 5.47% to $5.7 million in 2023, then slipped by 21.22% to $4.5 million in 2024, then jumped by 2515.22% to $116.5 million in 2025, then fell by 7.49% to $107.8 million in 2026.
- Business Quant data shows SGMT's Total Liabilities at $107.8 million in Q1 2026, $116.5 million in Q4 2025, and $128.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 7.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.28 Mn |
| Mar 31, 2026 | 107.76 Mn |
| Dec 31, 2025 | 116.48 Mn |
| Sep 30, 2025 | 128.40 Mn |
| Jun 30, 2025 | 137.41 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.09 Mn |
| Jun 30, 2024 | 5.73 Mn |
| Mar 31, 2024 | 4.51 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 5.05 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Dec 31, 2022 | 5.36 Mn |